The inhibitory immunoreceptor PD1 is a major cancer immunotherapy target. Anti-PD1 blockade antibodies have become the standard of care for cancer patients, but the low response rate and associated immune related side effects necessitate a better understanding of PD1 mechanism. Best known to be e...